Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02909218
Other study ID # MaxART
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date September 1, 2014
Est. completion date August 31, 2017

Study information

Verified date July 2018
Source Clinton Health Access Initiative Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the feasibility, acceptability, clinical outcomes, affordability, and scalability of offering early antiretroviral treatment to all HIV-positive individuals in Swaziland's government-managed health system.


Description:

The clinical evidence in support of offering antiretroviral treatment (ART) for all HIV-positive individuals to improve patient health outcomes and reduce HIV incidence is building, and the resource-limited countries where this approach could have the biggest impact want to evaluate if this is a feasible and effective intervention to turn the course of their HIV epidemics. The MaxART Early Access to ART for All (EAAA) implementation study was designed to determine the feasibility, acceptability, clinical outcomes, affordability, and scalability of offering early antiretroviral treatment to all HIV-positive individuals in Swaziland's government-managed health system.

This is a 3-year randomized stepped wedge design with open enrollment for all adults 18 years and older across 14 rural health facilities in Swaziland's Hhohho Region. Primary endpoints are retention and viral suppression. Secondary endpoints include ART initiation, adherence, drug resistance, tuberculosis, HIV disease progression, and cost per patient per year.

Sites are grouped to transition two at a time from the control (standard of care) to intervention (EAAA) stage at each 4-month step. This balanced design will result in approximately one half of the observations being under an intervention clinic, and the other half under control.

Power calculations were conservatively based on the estimated number of individuals expected to enroll in the study comparing the first 12-month measure of retention and 6-month of viral suppression on ART of those entering clinics during their control stage versus those that will be entering a clinic during intervention period.

A strategic mix of multidisciplinary research methodologies will be applied to meet the study aim, including implementation science, social science research, economic evaluations, and HIV incidence modeling.


Recruitment information / eligibility

Status Completed
Enrollment 3485
Est. completion date August 31, 2017
Est. primary completion date August 31, 2017
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- All ART-naive HIV-positive individuals who are 18 years of age or older - excluding pregnant or breastfeeding women - who attend the health facilities included in the study will be asked for their consent to enroll in the study.

Exclusion Criteria:

- All HIV-positive individuals who < 18 years of age or older and pregnant or breastfeeding women.

- All HIV-positive individuals who did not consent to participate or who have already been initiated on ART.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Early Access to ART for All
All HIV-positive individuals will be initiated on Swaziland's recommended first-line ART regimen, unless contraindicated when recommended alternate regimens will be used per national guidelines.

Locations

Country Name City State
Swaziland Swaziland Ministry of Health Mbabane

Sponsors (8)

Lead Sponsor Collaborator
Clinton Health Access Initiative Inc. Harvard School of Public Health, Ministry of Health, Swaziland, Southern African AIDS Information Dissemination Service (SAfAIDS), Southern African Centre for Epidemiological Modelling and Analyses (SACEMA), STOP AIDS NOW! (SAN!), Swaziland National Network of People Living with HIV/AIDS (SWANNEPHA), University of Amsterdam

Country where clinical trial is conducted

Swaziland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Retention Proportion of individuals retained in care or on ART at 12 months 12 months
Primary Viral suppression Proportion of individuals whose viral load is below 1,000 copies/ml (virally suppressed) after 6 months on ART 6 months
Secondary 12-month mortality rate mortality rate among clients newly enrolled in or returning to facilities during the standard of care phase is equal to 12-month mortality rate among clients newly enrolled in or returning to facilities during early ART phase 12 months
Secondary Visit adherence among those initiated on ART Proportion of missed visits as a number of scheduled appointments among ART-ineligible clients by end of follow-up 36 months
Secondary Drug resistance Proportion of drug resistance among ART-ineligible clients with two virological failures who have received genotype resistance testing 36 months
Secondary Tuberculosis Proportion of HIV-positive individuals diagnosed with new tuberculosis following enrollment (recurrent and newly incident). 36 months
Secondary ART uptake among those who are eligible Proportion of HIV-positive individuals who are eligible for initiation who are successfully initiated to ART within 1 and 3 months of becoming eligible 3 months
Secondary Cost per patient per year Bottom-up and top-town costing of the patient lifetime cost to test, treat, link, and retain individuals on ART 12 months
Secondary HIV infection Mathematical modeling to estimate the number of new adult HIV infections using empirical data from the primary endpoints 36 months
See also
  Status Clinical Trial Phase
Completed NCT03413696 - Effects of Health Literacy and HCV Knowledge on HCV Treatment Willingness in HIV-coinfected Patients
Completed NCT03215901 - Life Plans Intervention Study N/A
Completed NCT03289676 - Storytelling Narrative Communication Intervention for Smoking Cessation in Women Living With HIV Phase 1
Completed NCT03268551 - MEMO-Medical Marijuana and Opioids Study
Active, not recruiting NCT04064567 - Linking High-Risk Jail Detainees to HIV Pre-Exposure Prophylaxis: PrEP-LINK N/A
Completed NCT04121962 - A Pilot Peer Mentor Intervention That Trains Black Men Who Have Sex With Men (BMSM) to Use and Promote Uptake of HIV/STI Self-Testing to Peers and Sex Partners: STAR Study (Self-Testing at Your Residence) N/A
Completed NCT04013295 - Prize-linked Savings Initiatives for Promoting Better Health and Economic Outcomes in Kenya N/A
Recruiting NCT04405700 - Measuring Adverse Pregnancy and Newborn Congenital Outcomes
Recruiting NCT03984136 - HIV Results Exchange Mechanism on Promoting HIV Testing Among MSM N/A
Completed NCT02928900 - Patient Actor Training to Improve HIV Services for Adolescents in Kenya N/A
Recruiting NCT03268109 - COGnitive ImpairmenT in Older HIV-infected Patients ≥ 65 Years Old
Not yet recruiting NCT05813964 - Efficacy, Acceptability and Safety of Event-driven HIV PrEP Using TAF/FTC in MSM in Thailand and France. Phase 3
Completed NCT02797262 - Measuring and Monitoring Adherence to ART With Pill Ingestible Sensor System N/A
Completed NCT02376582 - Safety and Immunogenicity Study of a DNA Vaccine Combined With Protein Vaccine Against HIV/AIDS Phase 1
Completed NCT01957865 - Real-Time Antiretroviral Therapy Adherence Intervention in Uganda N/A
Completed NCT01616940 - Minority AIDS Initiative Retention and Re-Engagement Project N/A
Terminated NCT01443923 - Boceprevir Drug Combination for Hepatitis C Treatment in People With and Without HIV Phase 4
Completed NCT01910714 - Adapting and Evaluating an EBI to Prevent HIV/AIDS Risk Among Apache Youth N/A
Completed NCT01084421 - A Computer-Based Parent/Adolescent HIV Communication Intervention for Latinos N/A
Completed NCT01596322 - International HIV Antiretroviral Adherence, Resistance and Survival N/A